Weight loss drug "top selling", core drug under pressure Pfizer (PFE.US) wants to "buy buy buy" to increase investment in heart metabolism shortcomings.

According to the Zhidao Finance app, Pfizer (PFE.US) disclosed in its first quarter 2025 financial report that following setbacks in the development of the oral weight loss drug Danuglipron, the company will accelerate its expansion in the cardiovascular metabolism field through acquisitions or partnerships to fill the product line gap. The report showed that although Pfizer's Q1 revenue of $13.7 billion (an 8% decrease year-on-year) fell short of market expectations, adjusted earnings per share exceeded expectations, and the company maintained its upper limit profit guidance for the full year.